Imunon's latest marketcap:
As of 07/26/2025, Imunon's market capitalization has reached $9.94 M. According to our data, Imunon is the 40729th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 9.94 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -17,793,212 |
| Shares Out | 1.42 M |
| EPS (ttm) | -20.86 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/13/2025 |
Imunon's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/26/2025 | $9.94 M | -46.38% | 40729 |
| 12/31/2024 | $13.8 M | 115.62% | 36396 |
| 12/29/2023 | $6.4 M | -36% | 38842 |
| 12/30/2022 | $10 M | -78.59% | 35944 |
| 12/31/2021 | $46.7 M | 75.56% | 27971 |
| 12/31/2020 | $26.6 M | -31.62% | 28141 |
| 12/31/2019 | $38.9 M | 47.35% | 23245 |
| 12/31/2018 | $26.4 M | -38.6% | 24242 |
| 12/29/2017 | $43 M | 444.3% | 22306 |
| 12/30/2016 | $7.9 M | -82.29% | 25890 |
Company Profile
About Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies and next-generation vaccines.
Key Clinical Programs
- IMNN-001: A DNA-based immunotherapy for ovarian cancer, currently in Phase II clinical trials.
- IMNN-101: A preclinical COVID-19 booster vaccine candidate.
- IMNN-102: A treatment under development for the Lassa virus.
- IMNN-201: A Trp2 tumor-associated antigen cancer vaccine targeting melanoma.
Technology Platforms
The company leverages non-viral DNA technology across multiple modalities, including:
- TheraPlas: Designed for coding proteins and cytokines to treat solid tumors.
- PlaCCine: Focused on coding viral antigens to stimulate a robust immune response.
Corporate Background
Formerly known as Celsion Corporation, the company rebranded to Imunon, Inc. in September 2022. Founded in 1982, Imunon is headquartered in Lawrenceville, New Jersey.
Frequently Asked Questions
-
What is Imunon's (IMNN) current market cap?As of 07/26/2025, Imunon (including the parent company, if applicable) has an estimated market capitalization of $9.94 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Imunon (IMNN) rank globally by market cap?Imunon global market capitalization ranking is approximately 40729 as of 07/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.